771 related articles for article (PubMed ID: 25687206)
21. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.
Adar T; Faleck D; Sasidharan S; Cushing K; Borren NZ; Nalagatla N; Ungaro R; Sy W; Owen SC; Patel A; Cohen BL; Ananthakrishnan AN
Aliment Pharmacol Ther; 2019 Apr; 49(7):873-879. PubMed ID: 30773667
[TBL] [Abstract][Full Text] [Related]
22. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease.
Armuzzi A; Gionchetti P; Daperno M; Danese S; Orlando A; Lia Scribano M; Vecchi M; Rizzello F;
Dig Liver Dis; 2016 Apr; 48(4):360-70. PubMed ID: 26821929
[TBL] [Abstract][Full Text] [Related]
23. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
[TBL] [Abstract][Full Text] [Related]
24. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
Agrawal M; Zhang X; Brenner EJ; Ungaro RC; Kappelman MD; Colombel JF
J Crohns Colitis; 2021 Nov; 15(11):1877-1884. PubMed ID: 33884425
[TBL] [Abstract][Full Text] [Related]
25. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
[TBL] [Abstract][Full Text] [Related]
26. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
[TBL] [Abstract][Full Text] [Related]
27. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
Scribano ML
World J Gastroenterol; 2018 Jun; 24(23):2457-2467. PubMed ID: 29930467
[TBL] [Abstract][Full Text] [Related]
28. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
[TBL] [Abstract][Full Text] [Related]
30. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
Smith MA; Mohammad RA
Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
[TBL] [Abstract][Full Text] [Related]
31. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.
Lamichhane N; Melas N; Bergqvist V; ; Ekholm NP; Olén O; Ludvigsson JF; Hjortswang H; Marsal J; Eriksson C; Halfvarson J
Dig Dis Sci; 2024 Jun; 69(6):2175-2183. PubMed ID: 38637457
[TBL] [Abstract][Full Text] [Related]
32. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
33. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T
Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939
[No Abstract] [Full Text] [Related]
34. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.
Dubash S; Marianayagam T; Tinazzi I; Al-Araimi T; Pagnoux C; Weizman AV; Richette P; Tran Minh ML; Allez M; Singh A; Ciccia F; Hamlin J; Tan AL; Marzo-Ortega H; McGonagle D
Rheumatology (Oxford); 2019 Jun; 58(6):963-968. PubMed ID: 30204909
[TBL] [Abstract][Full Text] [Related]
35. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
36. Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.
Yarur AJ; Deepak P; Vande Casteele N; Battat R; Jain A; Okada L; Osterman M; Regueiro M
Dig Dis Sci; 2021 Oct; 66(10):3563-3569. PubMed ID: 33089483
[TBL] [Abstract][Full Text] [Related]
37. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
[TBL] [Abstract][Full Text] [Related]
38. A product review of vedolizumab in inflammatory bowel disease.
Battat R; Dulai PS; Jairath V; Vande Casteele N
Hum Vaccin Immunother; 2019; 15(10):2482-2490. PubMed ID: 30897022
[TBL] [Abstract][Full Text] [Related]
39. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
Battat R; Ma C; Jairath V; Khanna R; Feagan BG
Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
[TBL] [Abstract][Full Text] [Related]
40. Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting.
Kolehmainen S; Ylisaukko-Oja T; Jokelainen J; Koivusalo M; Jokiranta TS; Sipponen T
Scand J Gastroenterol; 2021 Aug; 56(8):906-913. PubMed ID: 34154506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
